Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of HSK39297 in lupus nephritis
CTR20254084Phase 2Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in lupus nephritis (LN) comparing HSK39297 arm with Placebo arm (2 arms). Primary endpoint: Ratio of 24-hour urine protein-to-creatinine ratio to baseline. Started Nov 2025; status: active.
02
Drugs
ciprocopan
03
Conditions
lupus nephritis (LN)
Beyond the preview
Go deeper on CTR20254084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254084.